Recital 283, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

In conclusion, the fines to be imposed, pursuant to Article 15(2)(a) of Regulation No 17, should be as follows:

–

Rhône-Poulenc Biochimie SA/Aventis Pharma SA: EUR 2,85 million

–

Merck KgaA: EUR 0 million.